Early phase oncology trials often require a continuous safety monitoring because of the unexpected toxicity associated with investigational agents. Safety monitoring becomes especially challenging in biomarker driven trials where each patient potentially receives a different treatment according to his/her biomarker profile. We propose to develop and evaluate continuous stopping boundaries for excess toxicity in the context of biomarker driven clinical trials.
